Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Weill Cornell Medicine

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
781
Shown on this page
12
Current sort
Recently updated
Campus scope
Weill Cornell Medicine, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Weill Cornell Medicine, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 745–756 of 781 matching trials with a site at Weill Cornell Medicine, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting No phase listed Observational

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

NCT01848561
Site status not listed — check the official record
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
8,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
169
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 31, 2026, 12:38 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04454658
Site status not listed — check the official record
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
ABBV-744, Navitoclax, Ruxolitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 31, 2026, 12:38 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
45
States / cities
Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 31, 2026, 12:38 PM EDT
Recruiting Early Phase 1 Interventional

GWICTIC: NAC Mechanistic Study in Gulf War Veterans

NCT04987775
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
N-Acetyl Cysteine, Placebo
Drug
Lead sponsor
Nova Southeastern University
Other
Eligibility
47 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Palo Alto, California • Fort Lauderdale, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 31, 2026, 12:38 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

NCT04006210
Site status not listed — check the official record
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD, Placebo for Oral IR-LD/CD
Combination Product · Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 31, 2026, 12:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

NCT05970497
Status at this site: Recruiting
View directory record Official record
Conditions
Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
Interventions
KB707, Opdualag, KEYTRUDA ®( Pembrolizumab)
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Rancho Santa Margarita, California • Weston, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 31, 2026, 12:38 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

NCT04730258
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML
Interventions
CFI-400945, Azacitidine
Drug
Lead sponsor
Treadwell Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Duarte, California • Sacramento, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 31, 2026, 12:38 PM EDT
Recruiting Not applicable Interventional

Serrantor OCT Study

NCT06434194
Status at this site: Recruiting
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Serranator PTA Serration Catheter, PTA (Standard of Care)
Device · Drug
Lead sponsor
Cagent Vascular LLC
Industry
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 31, 2026, 12:38 PM EDT
Active, not recruiting Not applicable Interventional

Bilateral Treatment of Medication Refractory Essential Tremor

NCT04112381
Site status not listed — check the official record
View directory record Official record
Conditions
Essential Tremor
Interventions
Exablate Model 4000 Type 1.0/1.1
Device
Lead sponsor
InSightec
Industry
Eligibility
22 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Stanford, California • Baltimore, Maryland • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 31, 2026, 12:38 PM EDT
Active, not recruiting Phase 1 Interventional

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

NCT04420754
Site status not listed — check the official record
View directory record Official record
Conditions
Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer
Interventions
AIC100 CAR T Cells
Biological
Lead sponsor
AffyImmune Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 31, 2026, 12:38 PM EDT
Recruiting Phase 1 Interventional

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

NCT05190471
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions
BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (in combination with BP1002)
Drug
Lead sponsor
Bio-Path Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 31, 2026, 12:38 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

NCT02781883
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
BP1001 in combination with Ventoclax plus decitabine, BP1001 plus decitabine
Drug
Lead sponsor
Bio-Path Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Augusta, Georgia • Fairway, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 31, 2026, 12:38 PM EDT

About this Weill Cornell Medicine institution page

What this page lists
ClinicalTrials.gov records that list Weill Cornell Medicine in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.